hydrochlorothiazide has been researched along with Stroke in 29 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 9.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic hypertension (ISH)." | 9.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 9.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats." | 7.77 | Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011) |
| " Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)." | 7.75 | Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 7.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 6.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension." | 6.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 6.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| " The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events." | 5.20 | Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. ( Asp, J; Dahlöf, B; Jamerson, KA; Jia, Y; Kjeldsen, SE; Östergren, J; Skoglund, PH; Svensson, P; Weber, MA; Zappe, DH, 2015) |
| " The aim of this study was to elucidate whether hydrochlorothiazide additionally exerts such effects in stroke patients under treatment with losartan." | 5.20 | Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study. ( Ago, T; Hata, J; Ibayashi, S; Kamouchi, M; Kitazono, T; Kusuda, K; Nagao, T; Nakane, H; Omae, T, 2015) |
| "The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic hypertension (ISH)." | 5.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "To test the hypothesis that losartan improves outcome better than atenolol in patients with isolated systolic hypertension and electrocardiographically documented left ventricular hypertrophy (ECG-LVH)." | 5.10 | Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. ( Aurup, P; Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, J; Fyhrquist, F; Ibsen, H; Julius, S; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, S; Wedel, H, 2002) |
| "To evaluate the efficacy and safety of the polypill for prevention of cardiovascular disease (CVD) and stroke and to present literature related to the polypill components (statin, aspirin, antihypertensive) for primary prevention of CVD and stroke." | 4.88 | A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. ( Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO, 2012) |
| "The vascular protective effects of placebo, candesartan (1 mg kg(-1) per day) monotherapy, candesartan (1 mg kg(-1) per day) and amlodipine (1 mg kg(-1) per day) combination therapy, and candesartan (1 mg kg(-1) per day) and hydrochlorothiazide (HCTZ) (10 mg kg(-1) per day) combination therapy for 2 weeks were compared in stroke-prone, spontaneously hypertensive rats." | 3.77 | Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Shimosato, T; Takai, S, 2011) |
| "There is significant controversy around whether chlorthalidone (CTD) is superior to hydrochlorothiazide (HCTZ) in hypertension management." | 3.77 | Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. ( Bleske, BE; Dorsch, MP; Erickson, SR; Gillespie, BW; Weder, AB, 2011) |
| " Therefore, olmesartan, an angiotensin type 1 receptor blocker, might affect oxidative stress in the brains of stroke-prone spontaneously hypertensive rats (SHRSP)." | 3.75 | Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method. ( Araki, S; Hirooka, Y; Kishi, T; Sunagawa, K; Utsumi, H; Yasukawa, K, 2009) |
| "A total of 500 outpatients with primary AH and risk factors including the risk of stroke received Hyzaar (losartan 50/100 mg and hydrochlorthiaside 12." | 3.75 | [Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program]. ( Bubnova, MG; Oganov, RG, 2009) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 3.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "Treatment with losartan (+/- HCTZ) was well tolerated and led to a substantial decrease in blood pressure and associated stroke risk." | 2.73 | Impact of losartan on stroke risk in hypertensive patients in primary care. ( Bestehorn, K; Wahle, K, 2007) |
| "Losartan/HCTZ is an effective combination therapy, lowering blood pressure (BP) to a greater extent than losartan or HCTZ alone in patients with hypertension." | 2.45 | Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy. ( Keating, GM, 2009) |
| "Losartan was frequently administered with hydrochlorothiazide in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, in which there was a 25% risk reduction for stroke in the losartan-based compared with the atenolol-based treatment group." | 2.44 | Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke. ( Høieggen, A; Kizer, JR; Kjeldsen, SE; Lyle, PA; Oparil, S; Os, I, 2007) |
| " The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect." | 1.32 | Introduction to monitoring. What is what you prescribed actually doing? ( George, A; Shakib, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (68.97) | 29.6817 |
| 2010's | 9 (31.03) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Skoglund, PH | 1 |
| Svensson, P | 1 |
| Asp, J | 1 |
| Dahlöf, B | 3 |
| Kjeldsen, SE | 4 |
| Jamerson, KA | 1 |
| Weber, MA | 3 |
| Jia, Y | 2 |
| Zappe, DH | 2 |
| Östergren, J | 1 |
| Nakane, H | 1 |
| Kamouchi, M | 1 |
| Hata, J | 1 |
| Ibayashi, S | 1 |
| Kusuda, K | 1 |
| Omae, T | 1 |
| Nagao, T | 1 |
| Ago, T | 1 |
| Kitazono, T | 1 |
| Wald, NJ | 2 |
| Luteijn, JM | 2 |
| Morris, JK | 2 |
| Taylor, D | 1 |
| Oppenheimer, P | 1 |
| Keating, GM | 1 |
| Araki, S | 1 |
| Hirooka, Y | 1 |
| Kishi, T | 1 |
| Yasukawa, K | 1 |
| Utsumi, H | 1 |
| Sunagawa, K | 1 |
| Bubnova, MG | 1 |
| Oganov, RG | 1 |
| Takai, S | 1 |
| Jin, D | 1 |
| Shimosato, T | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Dorsch, MP | 1 |
| Gillespie, BW | 1 |
| Erickson, SR | 1 |
| Bleske, BE | 1 |
| Weder, AB | 1 |
| Carey, KM | 1 |
| Comee, MR | 1 |
| Donovan, JL | 1 |
| Kanaan, AO | 1 |
| Julius, S | 2 |
| Brunner, HR | 1 |
| Hua, TA | 1 |
| McInnes, GT | 1 |
| Schork, A | 1 |
| Mancia, G | 1 |
| Zanchetti, A | 4 |
| Devereux, RB | 1 |
| Aurup, P | 1 |
| Edelman, J | 1 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 2 |
| Snapinn, S | 1 |
| Wedel, H | 1 |
| Baumgart, P | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Graham, D | 1 |
| Hamilton, C | 1 |
| Beattie, E | 1 |
| Spiers, A | 1 |
| Dominiczak, AF | 1 |
| Staessen, JA | 1 |
| Thijisq, L | 1 |
| Fagard, R | 1 |
| Celis, H | 1 |
| Birkenhäger, WH | 1 |
| Bulpitt, CJ | 1 |
| de Leeuw, PW | 1 |
| Fletcher, AE | 1 |
| Forette, F | 1 |
| Leonetti, G | 1 |
| McCormack, P | 1 |
| Nachev, C | 1 |
| O'Brien, E | 1 |
| Rodicio, JL | 1 |
| Rosenfeld, J | 1 |
| Sarti, C | 1 |
| Tuomilehto, J | 1 |
| Webster, J | 1 |
| Yodfat, Y | 1 |
| Williams, B | 1 |
| Papademetriou, V | 1 |
| Farsang, C | 1 |
| Elmfeldt, D | 1 |
| Hofman, A | 1 |
| Lithell, H | 1 |
| Olofsson, B | 1 |
| Skoog, I | 1 |
| Trenkwalder, P | 1 |
| Liu, L | 1 |
| Zhang, Y | 1 |
| Liu, G | 1 |
| Li, W | 1 |
| Zhang, X | 1 |
| Cooper-Dehoff, R | 1 |
| Cohen, JD | 1 |
| Bakris, GL | 2 |
| Messerli, FH | 2 |
| Erdine, S | 1 |
| Hewkin, AC | 1 |
| Kupfer, S | 1 |
| Pepine, CJ | 2 |
| Bestehorn, K | 1 |
| Wahle, K | 1 |
| Pitt, B | 1 |
| Velazquez, E | 1 |
| Gupte, J | 1 |
| Lefkowitz, M | 1 |
| Hester, A | 1 |
| Shi, V | 1 |
| Weir, M | 1 |
| Kjeldsen, S | 1 |
| Massie, B | 1 |
| Nesbitt, S | 1 |
| Ofili, E | 1 |
| Jamerson, K | 1 |
| Soucek, M | 1 |
| Plachý, M | 1 |
| Lyle, PA | 1 |
| Kizer, JR | 1 |
| Høieggen, A | 1 |
| Os, I | 1 |
| Coca, A | 1 |
| Benetos, A | 1 |
| Zhou, Q | 1 |
| Champion, A | 1 |
| Cooper-DeHoff, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy[NCT02921321] | 100 participants (Anticipated) | Observational | 2014-01-31 | Active, not recruiting | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Stroke Prediction Study Using a Model Based on Internet Search Queries[NCT04755959] | 450 participants (Anticipated) | Observational | 2021-02-28 | Not yet recruiting | |||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for hydrochlorothiazide and Stroke
| Article | Year |
|---|---|
Losartan/Hydrochlorothiazide: a review of its use in the treatment of hypertension and for stroke risk reduction in patients with hypertension and left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Diuretics; Drug Combinati | 2009 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydr | 2012 |
Protection against stroke and dementia: an update on the latest clinical trial evidence.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2004 |
Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Drug Therapy, Combination; Humans; | 2007 |
11 trials available for hydrochlorothiazide and Stroke
| Article | Year |
|---|---|
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug T | 2015 |
Effects of hydrochlorothiazide on oxidative stress and pulse pressure in hypertensive patients with chronic stroke: the EMINENT study.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2015 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2012 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
Topics: Aged; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Double-Blind Method; Female; Human | 2002 |
Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus; Dihydrop | 2004 |
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Ch | 2005 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Body Mass Index; Calcium Chann | 2006 |
Impact of losartan on stroke risk in hypertensive patients in primary care.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Dr | 2007 |
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Diabetes Mellitus, Type 2; | 2007 |
[The FEVER (Felodipine EVEnt Reduction) trial; a randomised, double-blind, placebo-controlled trial in Chinese hypertensive patients].
Topics: Aged; Calcium Channel Blockers; China; Diuretics; Double-Blind Method; Felodipine; Female; Humans; H | 2007 |
14 other studies available for hydrochlorothiazide and Stroke
| Article | Year |
|---|---|
Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Cardiovascular Agents; Case-Control Studies; Cohort St | 2016 |
Starting the polypill: the use of a single age cut-off in males and females.
Topics: Adult; Age Factors; Aged; Cardiovascular Agents; Drug Combinations; Female; Humans; Hydrochlorothiaz | 2017 |
Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Brain; El | 2009 |
[Treatment of patients with arterial hypertension and other stroke risk factors in clinical practice. The PROGNOS program].
Topics: Aged; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hypertension; Losartan; Male; Middle A | 2009 |
Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats.
Topics: Acetylcholine; Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blo | 2011 |
Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis.
Topics: Adult; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Cholesterol; Heart | 2011 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Huma | 2011 |
[Fixed combination of AT1 blocker and diuretic. Stroke preventive combination for hypertension].
Topics: Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Stroke; Tetrazoles; Treatment Outcome; | 2002 |
[LIFE study proves preventive action. With losartan to do even more against stroke].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Diabetes Co | 2003 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Fa | 2003 |
Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Carba | 2004 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
[Plus point -- risk reduction].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents | 2006 |
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Black People; Coronary Artery Disease; D | 2008 |